David Sinclair· PhD
The TAME study to show the @US_FDA that aging is a disease that can be treated with metformin
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
The TAME study to show the @US_FDA that aging is a disease that can be treated with metformin
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
And we should know in the next few years if he's seeing signs of slowing aging and he's looking at a number of things, not just diseases, but also things like stability, ability to walk, strength, these kinds of things, mental acuity, these are things that would indicate that aging itself is being slowed down. And he's even now able to measure the human biological clock with accuracy. And that should also be slowed down if this is truly an anti-aging medicine.
The targeting of aging by Metformin study run by [indistinct] down at Albert Einstein College of Medicine, this is a very large study over many different institutes and hospitals. It's costing tens of millions of dollars. But ultimately the goal is to show to the American FDA that you can target aging with a drug and slow it down. The ultimate goal being having aging a treatable medical condition.
for us we're calculating the power I was just about to say the power analysis on that study is going to quadruple your budget not will for what they decide for the size of it for us it's not only it's not only the budget we don't want to stop the study let's say that we show in two years that we we delay cardiovascular disease it's significant they'll stop the study they said no everybody now has to be on metformin but we wouldn't be able to show the FDA that if we actually that we're aging for us aging is stopped telling us diseases we are going to have a cluster and we're just going to delay the aging so we'll get we'll get the health span extended by two three years that's what we're trying to show you and the significance is the for the cluster not for the individual disease and if you tell me to do individual disease I need tripled by their budgets and I'm not going to get to the FDA with the indication for aging
tain stands for taming or targeting aging with metformin and it's a study that's designed to prove the concept that aging can be targeted but also or mainly for me is for the FDA to give an approval to an indication that's like aging the first time I heard about tame was actually here in this city
i'm focused on achieving a goal that the fda you know metformin is the tool to pave the road for an indication that's all i'm trying to do
we needed to do look to st to start a study at 50 where you have to show mortality is a 20-year study we we we cannot afford it right so we needed to start it when people are starting to accumulate disease in order for us to have lots of events our hypothesis is that the the aging part of your biology doesn't stop working when you had your first disease it's still going to get your next disease okay and if we think biologically like that we should be able to intervene as we do with animals quite late also
i'm doing tame not because i don't believe in metformin because i need to have we need to have a tar a target that that's similar to aging okay that's the reason